CYP2D6 genetic polymorphisms are considered a major contributor to the large interindividual variability in CYP2D6-mediated drug metabolism, but fail to explain a significant portion of the variability. The aim of this study was to assess the ability of the CYP2D6 activity score (AS) estimated from CYP2D6 genotype to predict CYP2D6 expression and enzyme activity. The CYP2D6 gene region was sequenced in 115 healthy human liver tissue samples to determine their CYP2D6 AS. Additionally, CYP2D6 enzyme activity, protein, and mRNA levels were estimated. CYP2D6 AS explained 23% of the interindividual variability in CYP2D6 activity, but only 7.5% in tissues assigned AS 1-2. The CYP2D6 protein level was found to be the major determinant of CYP2D6 activity, explaining 59% of variability. These findings suggest that while CYP2D6 AS is a good predictor of poor metabolizer phenotype, additional nongenetic factors may govern the rate of CYP2D6-mediated metabolism in those without the poor metabolizer phenotype.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? þ CYP2D6 genetic polymorphisms have been considered a major contributor to large interindividual variability in CYP2D6-mediated drug metabolism in vivo.
WHAT QUESTION DID THIS STUDY ADDRESS?
þ How well CYP2D6 AS and genotypes serve as predictors of CYP2D6 activity for most human liver tissues has been unclear. WHAT THIS STUDY ADDS TO OUR KNOWLEDGE þ While the literature reports that CYP2D6 AS and genotypes are good predictors of PM and UM status, our data indicate that these factors are poor predictors of CYP2D6 activity for the majority of human liver tissue samples. HOW THIS MIGHT CHANGE CLINICAL PHARMA-COLOGY OR TRANSLATIONAL SCIENCE þ CYP2D6 genotyping for clinical dosing guidance may be most useful to identify patients who are poor metabolizers. For patients with an AS > 0, additional predictors may be needed to accurately predict CYP2D6 metabolizer status in vivo.
CYP2D6 is a major drug-metabolizing enzyme responsible for eliminating over 20% of clinically used drugs. 1 Substrates of CYP2D6 include tricyclic antidepressants (e.g., desipramine), selective serotonin receptor inhibitors (e.g., paroxetine), b-blockers (e.g., metoprolol), opioid analgesics (e.g., codeine), and anticancer agents (e.g., tamoxifen). 1 Notably, CYP2D6-mediated drug metabolism exhibits large interindividual variability. The urinary metabolic ratio (MR; a ratio of parent drug amount over metabolite amount) estimated after administration of a CYP2D6 substrate (e.g., dextromethorphan) ranges over several orders of magnitude in different individuals. 2 Based on the results from urinary MR, an individual can be classified as ultrarapid metabolizer (UM), normal metabolizer (NM), intermediate metabolizer (IM), or poor metabolizer (PM) of CYP2D6. 2 The CYP2D6 phenotype typically shows bimodal or trimodal distribution in European and US population, with PMs accounting for 5-10% of the populations. 2, 3 Genetic polymorphisms of CYP2D6 are considered a major contributor to interindividual variability in CYP2D6 activity. To date, over 100 CYP2D6 allelic variations have been identified. 4 These CYP2D6 variants can be characterized by the presence of single nucleotide polymorphisms (SNPs), gene hybrids with the pseudogene CYP2D7, gene deletion, or gene duplications/multiplications. 5 The outcomes can range from normal (e.g., CYP2D6*2), decreased (e.g., CYP2D6*10), increased (e.g., CYP2D6*13N), or no (e.g., CYP2D6*5) function of the CYP2D6 enzyme. Considering the large number and complexity of CYP2D6 genetic polymorphisms, the CYP2D6 activity score (AS) system was introduced as a simplified tool to estimate the contribution of CYP2D6 genotypes to clinical phenotype. 2 The previous study has shown a strong relationship between CYP2D6 AS and clinically observed MR of a CYP2D6 substrate, demonstrating that mean CYP2D6 activity increases with higher CYP2D6 AS.
Interestingly, while individuals with an AS of 0 (i.e., both CYP2D6 alleles are nonfunctional) were consistently found to exhibit the PM phenotype, substantial interindividual variability in CYP2D6 activity was observed in non-PM populations. For example, CYP2D6 activity (when determined by measuring urinary MR of dextromethorphan) exhibited significant overlaps among different groups of AS > 0. 2 Furthermore, large interindividual variability in CYP2D6 activity, ranging three orders of magnitude, was observed in wildtype (wt) carriers of CYP2D6.
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Of note, a distant enhancer SNP (rs5758550) linked to CYP2D6*2 is known to modulate the enhancer activity for CYP2D6 expression, 6 and differential urinary pH can alter urinary excretion of dextromethorphan and its metabolite (leading to variable urinary MR). 7 The extent of their contribution to differential CYP2D6 expression and activity is unclear. Together, the ability of CYP2D6 genetic polymorphisms to predict variability in CYP2D6-mediated drug metabolism remains to be further defined.
The goal of this study was to assess the ability of genotypederived CYP2D6 ASs to predict CYP2D6 expression and enzyme activity in the liver. To this end, we used highthroughput DNA sequencing to thoroughly identify CYP2D6 variants, and systematically evaluated the utility of CYP2D6 AS for the prediction of in vitro metabolic activity (and enzyme expression) in over 100 healthy human liver tissue samples.
RESULTS

Human liver tissue
In all, 115 liver tissue samples were included in the study (mean age 49 years; 70 males and 45 females). While age and sex are known not to affect CYP2D6-mediated drug metabolism, [8] [9] [10] these factors (including the source of liver tissues) were included in data analysis as potential covariates to ensure the robustness of the analysis. Ethnicity information was available for 50 of the samples (41 Caucasian, three African American, five Asian, and one Hispanic).
Variability in CYP2D6 activity explained by CYP2D6 AS CYP2D6 activity levels in the liver tissues were estimated by using a CYP2D6 probe drug, dextromethorphan. S9 fractions were used to minimize variability introduced during tissue preparation and processing. 11 Dextrorphan formation rate in the human liver S9 fractions exhibited large interindividual variability, ranging from 0.23-74 pmol dextrorphan/min/mg S9 protein (median 3.4 pmol/min/mg S9 protein) (Figure 1a) . The distribution of CYP2D6 activity followed log-normal distribution. Next, genetic polymorphisms of CYP2D6 gene were identified. The majority (n 5 94; 82%) of the tissues had two copies of CYP2D6. Eleven liver samples had one copy, and one sample had 0 copies. The remaining nine samples had a copy number of >2 when a probe targeting intron 6 of CYP2D6 was used (Figure 1b) .
The CYP2D6 gene region (9.4-kb total; from 4-kb upstream to 1-kb downstream) was sequenced by using high-throughput DNA sequencing complemented with Sanger sequencing. Eighteen CYP2D6 allelic variants (including three rare variants: *22, *23, and *108) and subsequently 38 CYP2D6 diplotypes were identified. We did not identify any novel nonsynonymous SNPs in CYP2D6 in this cohort of tissues. CYP2D6 alleles were assigned based on established CYP allele nomenclature, and the frequency of detected alleles is shown in Table 1 . CYP2D6 activity levels varied widely in the samples of different CYP2D6 genotypes ( Figure 1b) . Also, large variation in CYP2D6 activity was noted in the samples of the same genotype (e.g., CYP2D6*1/*1) (Figure 1b) . To evaluate the utility of AS in predicting CYP2D6 activity levels in liver tissue, AS was calculated for each liver sample. Median dextrorphan formation rate in AS 5 0 samples was 1.1 pmol/min/mg S9 protein ( Table 2 ). The median CYP2D6 activity levels in S9 fractions increased with AS ( Table 2 ; Figure 1c , P < 0.0001). However, large interindividual variability in CYP2D6 activity levels was observed within each AS category ( Figure 1a ). Considering that a distant enhancer SNP (rs5758550) linked to CYP2D6*2 can modulate the enhancer activity for CYP2D6 expression and thus CYP2D6 activity, 6 the SNP was detected in the samples of AS 5 2 and its association with CYP2D6 activity was examined. CYP2D6 activity level did not differ between rs5758550A and G genotypes (P 5 0.7; data not shown).
The extent of interindividual variability in CYP2D6 activity that can be explained by CYP2D6 AS was estimated by using linear regression analysis with adjustment for the covariates age, sex, and liver source. Overall, 23% of variability in CYP2D6 activity was explained by AS after adjustment for covariates. In the samples exhibiting AS of 1 to 2 (80% of the samples), AS accounted for 7.5% of the variability in CYP2D6 activity.
Variability in CYP2D6 activity explained by differential expression of CYP2D6
To further identify the sources of CYP2D6 variability, CYP2D6 protein expression in liver S9 fraction was measured by using semiquantitative western blots. In tissues with detectable CYP2D6 protein levels, the protein expression exhibited lognormal distribution ( Figure 2a ). Eleven liver samples exhibited CYP2D6 protein levels below the detection limit (equivalent to 0.5 in Figure 2a ); nine were carriers of two no-function CYP2D6 alleles (CYP2D6*4, *5, and *6). Interestingly, CYP2D6 protein was not detectable in two samples that carried only one no-function allele (CYP2D6*1/*4 and *4/*41) for as-yet unknown reasons. The mean CYP2D6 activity level of these 11 samples was 1.2 pmol dextrorphan production/min/mg S9 protein. Overall, CYP2D6 activity was highly correlated with its protein expression (Figure 2b , P < 0.0001), consistent with previous reports. [12] [13] [14] Results from regression analysis of all liver samples indicated that 59% of the variability in CYP2D6 activity could be explained by differential CYP2D6 protein expression when adjusted for sex, age, and liver source.
To examine whether genetic polymorphisms have any impact on the association between CYP2D6 protein expression and activity, we further examined the associations separately for each AS group. The association was examined only in the AS groups of 1, 1.5, and 2, as the other groups had very small sample sizes (i.e., n < 10). (a) Distribution of CYP2D6 protein levels (n 5 104). Not shown are 11 liver tissues whose CYP2D6 protein levels were below detection limit (i.e., relative CYP2D6 protein level of 0.5). (b) Overall correlation between CYP2D6 activity and protein expression in liver tissues with detectable CYP2D6 protein levels (n 5 104) is shown. The line denotes unadjusted linear regression of log CYP2D6 activity vs. log protein expression. CYP2D6 activity is expressed as dextrorphan (DX) formation rate in S9 fractions. (c) Correlation between CYP2D6 activity and protein expression stratified by AS is shown. The lines are unadjusted linear regression lines between log CYP2D6 activity and log CYP2D6 protein expression for each AS category. r 2 value is the square of adjusted correlation coefficient for all samples in the group. For AS 5 1 group, r 2 value is 0.54 for CYP2D6*4/wt carriers.
Association between CYP2D6 activity and protein levels was strongest in the AS 5 2 group, and were less robust in the samples with a lower AS (Figure 2c ). To determine whether genetic heterogeneity may diminish the correlation, association between CYP2D6 activity and protein levels was examined separately for the carriers of common CYP2D6 variants. Within the AS 5 1 group, the association between CYP2D6 activity and protein levels in (the most frequent) CYP2D6*4/wt carriers was stronger compared to that for the whole AS 5 1 group (Figure 2c ; adjusted r 2 5 0.54 vs. 0.33, for *4/wt and the whole AS 5 1 groups, respectively).
To determine the extent of variability in the CYP2D6 activity level that could be explained by differential transcription of the value is the square of adjusted correlation coefficient. (c) Overall correlation between CYP2D6 protein and mRNA levels in tissues with detectable CYP2D6 protein levels (n 5 104) is shown. r 2 value is the square of adjusted correlation coefficient. (d) CYP2D6 mRNA (left) and protein (right) expression in CYP2D6 wt/wt, *4 (i.e., *4/*4, *4/wt) and *41/wt carriers is shown. Welch's t-test was conducted between wt group and *4 group (or *41 group). **P < 0.01. (e) Correlation between CYP2D6 protein and mRNA levels is shown. Open circles represent the carriers of *4, *6, *41 *4x2 and *36x2 alleles (n 5 41) that were excluded from regression analysis. Filled dots represent the rest of samples (n 5 63) that were included in regression analysis, and corresponding r 2 value and linear regression line (log CYP2D6 protein vs. log CYP2D6 mRNA) are shown.
gene, we examined CYP2D6 mRNA expression by quantitative real-time polymerase chain reaction (qRT-PCR). The distribution of CYP2D6 mRNA levels was generally log-normal (Figure 3a) , and one tissue (the only CYP2D6*5/*5 carrier in our study) had no amplification, from a CYP2D6 gene deletion.
Results from the regression analysis showed that CYP2D6 activity levels are significantly correlated with the mRNA levels in tissues of AS > 0 (Figure 3b , P < 0.0001), with an adjusted r 2 value of 0.25 (r 2 5 0.21 when all 115 samples were analyzed). Considering that the amount of variability in CYP2D6 activity explained by differential mRNA levels is much smaller than that observed with CYP2D6 protein levels, the sources of disconnect between CYP2D6 mRNA and activity levels were explored. Specifically, the relationship between CYP2D6 protein and mRNA levels in the liver tissues was examined. The CYP2D6 protein level was significantly associated with its mRNA expression (Figure 3c ; adjusted r 2 5 0.11; P < 0.0001). Considering that certain genetic polymorphisms in CYP2D6 that are expected to cause the disconnect between mRNA and protein levels (e.g., CYP2D6*4 allele causing a frameshift in protein translation 15 or CYP2D6*41 favoring the production of an mRNA splice variant lacking exon 6 16 , correlation between CYP2D6 mRNA and protein levels was examined in the absence of such variants. The mRNA levels of CYP2D6 in carriers of the CYP2D6*1 and *2 alleles (i.e., wt carriers) did not differ from CYP2D6*4 or *41 carriers (Figure 3d) , whereas CYP2D6 protein levels significantly decreased in *4 carriers and showed a trend toward decreased levels (P 5 0.06) in *41 carriers when compared with wt carriers. In the carriers of CYP2D6*4 (frameshift), *6 (frameshift), *41 (splicing defect) and *36 (CYP2D7 gene hybrid) alleles (i.e., open circles in Figure 3e ), CYP2D6 protein and mRNA levels did not correlate (P 5 0.54). In the remaining samples, the correlation between CYP2D6 mRNA and protein levels improved to the adjusted r 2 value of 0.17 (from r 2 5 0.11) (Figure 3e ). This level of correlation was similar to that in the carriers of wt only (n 5 37; r 2 5 0.17; data not shown).
DISCUSSION
This is the first study, to our knowledge, that quantitatively assessed the ability of CYP2D6 genetic polymorphisms and AS to predict CYP2D6 expression and activity levels in human liver tissue. A systematic approach was undertaken to detect nearly all CYP2D6 genotypes (including rare variants) and measure mRNA, protein, and activity levels of CYP2D6 in over 100 snap-frozen healthy human liver tissues. This allowed examination of the CYP2D6 genotype-phenotype relationship in the absence of potential confounding factors that can affect the CYP2D6 phenotype in vivo, such as urinary pH. CYP2D6 activity in the samples exhibited large interindividual variability and apparent log-normal distribution, consistent with the previous results for CYP2D6 activity or protein levels in hepatic microsomes. 17, 18 The frequencies of different genotypes and copy number variation of CYP2D6 observed in this study were comparable to the reported values in those of European descent or the US population. 19, 20 Also, the distribution of CYP2D6 AS in our liver cohort was comparable to that previously reported in a population of European ancestry. 19 Consistent with clinical observations using dextromethorphan urinary MR or metoprolol AUC as markers of CYP2D6 activity levels, 2,21 a significant positive correlation between AS and CYP2D6 activity was observed. However, CYP2D6 activity levels within each AS category varied widely (over two orders of magnitude), and extensive overlap among different AS categories was observed especially in the samples with AS > 0. Overall, AS explained 23% of the interindividual variability in CYP2D6 activity. In the tissue samples with an AS of 1-2 (conventionally associated with NM phenotype; >80% of samples), the portion of CYP2D6 variability in activity explained by AS shrunk to 7.5%. No-function alleles of CYP2D6 (i.e., CYP2D6*4, *5, *6, and *12) alone accounted for 14% of the variability in CYP2D6 activity, suggesting that the overall CYP2D6 genotypephenotype association may be driven primarily by the effect of no-function CYP2D6 alleles in the tissues. The extent of overall association between CYP2D6 AS and enzyme activity observed in our samples is much smaller as compared to the clinically reported studies where 50-60% of variability in urinary MR (of dextromethorphan) is explained by CYP2D6 genotypes and AS.
2 A different magnitude of variability (i.e., urinary MR and hepatic CYP2D6 activity varying over six and three orders of magnitude, respectively) may in part explain the difference. MR (dextromethorphan/dextrorphan amount ratio) reflects changes in the amount of both the parent drug and metabolite. This can potentially magnify the distinction between PM and non-PM subjects, leading to larger CYP2D6 variability in urinary MR than in liver tissues, as well as a greater extent of CYP2D6 variability explained by CYP2D6 AS and genotypes.
In liver samples with AS > 0, CYP2D6 activity was highly correlated with its protein level, suggesting that CYP2D6 protein expression governs its activity levels in the liver, consistent with previous reports. 13, 14, 22 Nearly 60% of the variability in CYP2D6 activity can be explained by differential CYP2D6 protein expression in the tissues. Multiple factors may account for the remaining variability. First, while dextromethorphan O-demethylation (to form dextrorphan) is mediated primarily by CYP2D6, other CYPs are known to mediate this biotransformation at a slower rate. 23, 24 Consistent with this notion, we found that a small amount of dextrorphan was formed in liver tissues carrying only no-function CYP2D6 alleles (i.e., AS 5 0). Second, prior medication use of liver tissue donors may have impacted CYP2D6 enzyme activity. Many drugs including paroxetine (a commonly used antidepressant) are mechanism-based inhibitors of CYP2D6 and can decrease enzyme activity without affecting protein levels. 25, 26 The list of medications used by donors was not available for the liver tissues used in this study. Third, the presence of glucuronidation cofactors in S9 fractions (used in this study) may have enabled dextrorphan glucuronidation to occur to varying extents. However, the basal concentration of UDP glucuronic acid (the cofactor for glucuronidation reaction) in our S9 fraction is estimated to be 5 lM, 27 and since the k m values of UDP glucuronic acid for the typical substrates of glucuronidation enzymes are >100 lM, 27 the impact of dextrorphan glucuronidation on estimation of CYP2D6 enzyme activity should be minimal. Fourth, the CYP2D6 antibody used in this study to measure protein quantity in human liver S9 fractions may not detect certain CYP2D6 variants. The epitope for the antibody used in our study has not been mapped, and thus it is not known whether the antibody has similar binding affinity to CYP2D6 proteins from variant CYP2D6 alleles. Fifth, differential expression and/or activity of CYP partners including cytochrome P450 oxidoreductase (POR) 28 and cytochrome b5 29 may in part contribute to interindividual variability in CYP2D6 activity, but their levels were not measured in this study.
To test whether CYP2D6 expression at the mRNA level can serve as a predictor of CYP2D6 activity in the liver tissues, we examined the association between CYP2D6 mRNA and activity levels. CYP2D6 mRNA expression in AS > 0 samples accounted for about 25% of CYP2D6 activity, which is consistent with previously reported correlations between CYP2D6 microsomal activity and CYP2D6 mRNA levels in human liver tissue. 9 Interestingly, CYP2D6 mRNA levels correlated worse with protein levels (adjusted r 2 of 0.11) than enzyme activity, indicating that mRNA is likely a poor predictor of CYP2D6 activity in vivo. Further, this finding likely reflects the dynamic nature of the transcription and translation processes. For example, the estimated half-life of CYP2D6 mRNA is 4.8 h 30 while CYP2D6 protein half-life is 51-70 h. 31, 32 Due to the multiple steps involved in the regulation of gene expression in dynamic biological processes, the correlation between CYP protein and mRNA levels is expected to be imperfect, even when gene expression is governed entirely at the transcriptional level. 33 Human liver tissues used in this study likely provide a snapshot view of this dynamic biological process. Of note, accumulating evidence suggests that factors modulating CYP2D6 transcription are capable of regulating CYP2D6 expression and thus the enzyme activity. 9, 13, 17, 34, 35 Pharmacological or pathological induction of a small heterodimer partner, the transcriptional repressor of CYP2D6 expression, was shown to decrease CYP2D6 expression in CYP2D6-humanized transgenic mice. [36] [37] [38] How much these factors (that modulate CYP2D6 transcription) contribute to interindividual variability in CYP2D6 expression remains to be determined.
Our findings support the continued use of genotyped-derived CYP2D6 AS to predict poor metabolizers when administering drugs that are CYP2D6 substrates. We detected substantial variability in the CYP2D6 enzyme activity of samples with an AS > 0 ( Figure 1, Table 2 ). This, coupled with the relatively poor correlation we observed between AS and CYP2D6 activity, indicate that AS alone may not be sufficient to estimate a patient's CYP2D6 metabolizer status beyond that of a poor metabolizer. Our cohort only contained one sample with an AS > 3, and its CYP2D6 activity was within the ultrarapid metabolizer range; however, due to the small sample size, we are unable to conclude whether or not AS > 3 is a reliable estimate of UM status. While our findings suggest that CYP2D6 protein levels are, by far, the strongest predictor of enzyme activity, obtaining liver tissue samples are not practical in the clinical setting. Thus, additional factors such as concomitant CYP2D6 substrate use and patient-specific health conditions that affect CYP2D6 expression (e.g., pregnancy 39 ) must also be considered when attempting to predict a patient's metabolizer status.
To improve the predictive ability of the genotype-derived AS, additional research is needed to better characterize the functional effects of less common CYP2D6 polymorphisms on enzyme activity in vivo. For example, the two samples with the lowest CYP2D6 activity and protein expression in our cohort had *10/*23 and *4/*108 genotypes. CYP2D6.23 was previously shown to exhibit the enzyme activity comparable to the wt CYP2D6 (using tamoxifen as a CYP2D6 substrate), 40 and enzyme activity of CYP2D6.108 is unknown. A value of 1 was assigned to each, *23 and *108, to calculate AS of 1.5 and 1 for these samples, respectively. However, our data suggest that they may be either decreased or no-function alleles (due to altered CYP2D6 expression and/or activity). Such potential misclassifications would clearly affect AS accuracy, and better functional characterization of CYP2D6 variants would likely make the genotype-derived AS more reliable.
In conclusion, we identified the CYP2D6 protein level as the major predictor of enzyme activity in healthy human livers. Our results suggest that CYP2D6 AS is a reasonable predictor of CYP2D6 activity for PMs, but not necessarily for NMs. Moreover, we found that CYP2D6 mRNA levels possess a similar predictive value to AS. Further research is needed to determine the extent of contribution by differential CYP2D6 transcription to interindividual variability in CYP2D6-mediated drug metabolism.
METHODS
Human liver tissue
Frozen normal human liver tissue samples without gross pathology were obtained from Liver Tissue and Cell Distribution System (LTCDS, funded by NIH Contract #HHSN276201200017C) and Corning (Corning, NY). Mean ages of donors were 49.4 6 16.1 from the LTCDS (n 5 65; 32 males and 33 females) and 49.4 6 14.7 for Corning tissues (n 5 50; 38 males and 12 females).
CYP2D6 genotyping
Genomic DNA was extracted from human liver tissues using Gentra Puregene tissue kit (Qiagen, Chatsworth, CA). To ensure accuracy in detecting CYP2D6 CNV, two Taqman assays targeting intron 6 or exon 9 of CYP2D6 gene, Hs00010001_cn and Hs04502391_cn (ThermoFisher, Pittsburgh, PA), were used. Discrepancy between results from two assays (observed for two samples) was deemed caused by the presence of the CYP2D6*36 allele and multiple copies of the CYP2D6*4 allele that contain CYP2D7 gene conversion at exon 9, subsequently interfering with exon 9 CNV assay.
SNPs in CYP2D6 were examined using Ampliseq panels for target capture followed by Ion Torrent sequencing. The exon regions that could not be covered by the Ampliseq panel were sequenced using Sanger sequencing. Sequences were obtained from 4-kb upstream of the transcriptional start site to 1-kb downstream of the CYP2D6 gene (hg19 chr22:42521501-42530883). Raw data from Ion Torrent sequencing was filtered for quality control and aligned to hg19 genome assembly. SNP-calling was completed using GATK (https://software.broadinstitute.org/gatk/). All the SNPs were further filtered and curated manually based on sequencing quality and Hardy-Weinberg equilibrium. Sanger sequencing results for CYP2D6 were aligned to hg19 chr22:42525025-42525235 using novoSNP software. 41 CYP2D6 genotype assignment was based on CYP2D6 allele nomenclature 4 and previously published literature. 5 CYP2D6 AS was assigned to each sample as previously described. 2 
Measurement of CYP2D6 activity
Frozen human liver tissue (150 mg) was used to prepare hepatic S9 fraction as previously described. 36 CYP2D6 activities in S9 fractions were estimated using the formation rate of dextrorphan (from dextromethorphan) as a marker. The concentrations of dextrorphan in the reaction were measured by using liquid chromatography tandem mass spectrometry.
Semiquantitative western blotting CYP2D6 relative protein expression in S9 fraction was determined by semiquantitative western blotting using mouse monoclonal Gentest antihuman CYP2D6 antibody (catalog #458246, Corning).
RNA isolation and qRT-PCR Total RNA was extracted using TRIzol reagent (ThermoFisher) from human liver tissue samples. RNA quality was examined by agarose gel electrophoresis. Samples without two sharp bands of ribosomal RNA were excluded from the study. qRT-PCR was performed as previously described 36 using the following probes: IDT (catalog #Hs.PT.56a.45336286.g; targeting exon1-1 region; detecting all CYP2D6 variants) and ThermoFisher (catalog #Hs00164385_m1, targeting exon 2-3 region of CYP2D6 variant 1, NM_000106.5; detecting most CYP2D6 variants) for CYP2D6; ThermoFisher (catalog #Hs02800695_m1) for HPRT1.
Statistical analysis
Statistical analysis was performed using SAS v. 9.4 (Cary, NC). All variables of interest (predictors and outcomes) were assessed for normality; nonnormal distributions were normalized using log transformations. To determine basic predictor-outcome associations, a series of unadjusted linear regression analyses were conducted first. Based on these analyses, linear regressions whereby each predictor was examined in relation to the outcome after adjusting for age, sex, and source of liver were conducted.
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